⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
PRLD News
Prelude Therapeutics Incorporated
Form 8-K
sec.gov
PRLD
Prelude Therapeutics Announces Pricing of $90.0 Million Underwritten Offering
globenewswire.com
PRLD
Form 8-K
sec.gov
PRLD
Prelude Therapeutics Presents Preclinical Data from Development Candidate, PRT13722, a First-in-Class, Orally Bioavailable, Potent and Highly Selective KAT6A Degrader at American Association for Cancer Research (AACR) Annual Meeting 2026
globenewswire.com
PRLD
Form 8-K
sec.gov
PRLD
Prelude Therapeutics Announces Acceptance of Preclinical Abstract for PRT13722, a First-in-Class Oral KAT6A Selective Degrader at the 2026 AACR Annual Meeting
globenewswire.com
PRLD
Form 8-K
sec.gov
PRLD
PreludeDx Announces Publication in Breast Cancer Research Validating AidaBreast™, the Only Multi-Omic Test to Predict Locoregional Recurrence Risk and Radiation Therapy Benefit in Early-Stage Invasive Breast Cancer
prnewswire.com
PRLD
Form 8-K
sec.gov
PRLD
Prelude Therapeutics Reports Full Year 2025 Financial Results and Provides Program Outlook for 2026
globenewswire.com
PRLD